Circulating tumor DNA can help differentiate pseudoprogression from true progression in patients with melanoma who are treated with PD-1 inhibitors.
In a Belgian study, integration of palliative care as part of cancer care increased the quality of life of patients with advanced malignant solid tumors.
Patients with ER-negative, but not ER-positive, isolated locoregional recurrence after unilateral breast cancer derive significant benefit from chemotherapy.
The observed narrowing of racial disparities in prostate cancer outcome since the advent of PSA screening is not as large as previously believed.
A retrospective review found that obesity is associated with improved progression-free and overall survival in certain patients with metastatic melanoma.
Single-agent ibrutinib resulted in sustained efficacy and durable responses in treatment-naive or relapsed/refractory CLL or SLL, 5-year results show.
A preplanned analysis of ctDNA found that a subpopulation of mCRC patients with acquired anti-EGFR resistance were sensitive to treatment with Sym004.
The addition of metronomic chemotherapy to dual HER2 blockade improved outcomes in older and frail patients with HER2-positive metastatic breast cancer.
Cabozantinib showed significant antitumor activity in the treatment of differentiated thyroid cancer that progressed following surgery and radioactive iodine therapy, according to a new phase II study.
An early phase trial found that it is feasible to combine nivolumab immunotherapy with radiation therapy and chemotherapy in patients with newly diagnosed local-regionally advanced head and neck cancers.